Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

SLRX

Salarius Pharmaceuticals (SLRX)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLRX
DataOraFonteTitoloSimboloCompagnia
11/03/202511:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/03/202511:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
03/02/202514:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersNASDAQ:SLRXSalarius Pharmaceuticals Inc
21/01/202514:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SLRXSalarius Pharmaceuticals Inc
13/01/202514:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
13/01/202514:00GlobeNewswire Inc.Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementNASDAQ:SLRXSalarius Pharmaceuticals Inc
30/12/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/12/202422:35Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
01/11/202422:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRXSalarius Pharmaceuticals Inc
01/11/202422:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SLRXSalarius Pharmaceuticals Inc
09/08/202423:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202414:00GlobeNewswire Inc.Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202414:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/03/202421:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202414:00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesNASDAQ:SLRXSalarius Pharmaceuticals Inc
16/01/202414:00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
03/01/202414:30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNASDAQ:SLRXSalarius Pharmaceuticals Inc
07/11/202314:30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/10/202321:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/08/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/07/202314:30GlobeNewswire Inc.Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202314:00GlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/06/202312:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SLRXSalarius Pharmaceuticals Inc
07/06/202313:28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/06/202323:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
26/05/202323:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLRX

La tua Cronologia

Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network